ONCAlert | 2017 San Antonio Breast Cancer Symposium

The Efficacy of Dabrafenib in Pediatric Patients With BRAF V600-Mutant Low-Grade Gliomas

Mark Kieran, MD, PhD
Published Online: 2:44 PM, Sun October 9, 2016


Mark Kieran, MD, PhD, director, Pediatric Medical Neuro-Oncology, Dana-Farber Cancer Institute, discusses the results of a study that evaluated dabrafenib (Tafinlar) as a treatment for pediatric patients with BRAF V600-mutant relapsed or refractory low-grade gliomas during an interview at the 2016 ESMO Congress.

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.